

# The Effect of Health-Related Behaviors on Disease Progression and Mortality in Early Stages of Chronic Kidney Disease: A Nationwide Population-Based Study

Yookyung Lee<sup>1</sup>, SuYeon Kwon<sup>1</sup>, JongJoo Moon<sup>2</sup>, Kyungdo Han<sup>3</sup>, Nam-Jong Paik<sup>1</sup> and Won-Seok Kim<sup>1,\*</sup>

<sup>1</sup> Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea; [yookon@gmail.com](mailto:yookon@gmail.com) (Y.L); [sykwon0502@gmail.com](mailto:sykwon0502@gmail.com) (S.Y.K); [njpaik@snu.ac.kr](mailto:njpaik@snu.ac.kr) (N.J.P)

<sup>2</sup> Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; [jongjoomoon114@gmail.com](mailto:jongjoomoon114@gmail.com)

<sup>3</sup> Department of Biostatistics, The Catholic University of Korea College of Medicine, Seoul, South Korea; [hkd917@naver.com](mailto:hkd917@naver.com)

\* Correspondence: [wondol77@gmail.com](mailto:wondol77@gmail.com); Tel.: +82-31-787-7735

**Abstract:** Healthy life style is associated with decreased risk of chronic kidney disease (CKD) and mortality in the general population. However, there is no definitive evidence on the benefits of physical activity and other health-related behaviors in the early-stage CKD. This study aimed to explore the association between health-related behaviors and end-stage renal disease (ESRD) and mortality in the early stages of CKD. The National Health Insurance Service (NHIS) database from January 1<sup>st</sup>, 2009 to December 31<sup>st</sup>, 2016 was used to screen 83,470 subjects with early stage CKD. Cox proportional hazard regression analysis was used to evaluate the association between health-related behaviors and ESRD and death. Kaplan-Meier curves for mortality and ESRD were plotted according to the physical activity, smoking status and alcohol consumption pattern. Risk of death decreased significantly in subjects who engaged in sufficient physical activity (adjusted Hazard Ratio (HR) 0.73; 95% CI: 0.64-0.83;  $p < 0.001$ ). Risk of ESRD and death increased significantly in the current smoker with adjusted HR of 1.44 (95% CI: 1.06-1.95;  $p < 0.02$ ) and 1.61 (95% CI: 1.44-1.80;  $p < 0.001$ ) respectively. Therefore, systematic interventions to encourage physical activity and smoking cessation need to be actively considered in the early stages of CKD.

**Keywords:** Chronic kidney disease; Disease progression; End stage renal disease; Mortality; Health-related behaviors; Physical activity; Smoking; Alcohol;

## 1. Introduction

Chronic kidney disease (CKD) is a major global health burden due to its high prevalence and economic cost. The world-wide prevalence of CKD is estimated to be from 11 to 13 % [1]. Increasing prevalence of hypertension, diabetes, and aging societies suggests that the number of CKD patients will further increase in the future [2]. In developed countries, more than 1% of the total health budget is dedicated to the treatment of 0.1% of the population with end-stage renal disease (ESRD) [3].

Previous studies have investigated the relationship between health-related behaviors and CKD in the general population [4–7]. Regular exercise was associated with lower risk of CKD [7]. In a recent meta-analysis, smoking was shown to be an independent risk factor for CKD [6]. Alcohol consumption was associated with decreased risk of CKD [4]. These studies implicate that lifestyle modification may be important in preventing CKD.

According to the 2012 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines, exercise and smoking cessation are recommended for CKD patients [8]. Exercise may delay the decline of kidney function [9] and lower the risk of cardiovascular disease (CVD), for

47 which CKD is a risk factor [10]. Although the benefits of healthy life style on disease progression  
 48 and mortality in CKD patients seem straightforward, evidence is sparse, especially in patients with  
 49 early stages of CKD, who may be the best candidates to benefit from health behavior modifications.  
 50 Most studies evaluating the relationship between exercise and CKD have been limited by small  
 51 sample size [9]. Studies including early-stage CKD patients are relatively few and inconclusive [11].  
 52 There have been mixed results with respect to the effect of alcohol on CKD, with some reporting  
 53 protective effects while other reporting increased risk [12,13].

54 Therefore, the objective of this study was to investigate the real-world impact of health-related  
 55 behavioral change on CKD progression and mortality using nationally representative data.  
 56


## 57 2. Materials and Methods

### 58 2.1. Data source

59 Most Koreans (97.0%) residing in Korea are covered by one of two health care programs under  
 60 the National Health Insurance system: the National Health Insurance (NHI) or Medical Aid (MA)  
 61 [14]. Information on patient demographics, medical service use, disease diagnosis and life style  
 62 from the two health care programs are incorporated into a single National Health Insurance Service  
 63 (NHIS) database, accessible for researchers. The Korean NHIS also provides biannual health  
 64 check-ups which include a questionnaire on past medical history and health-related behaviors,  
 65 measurements of height, weight, blood pressure, blood count and blood chemistry test [14].  
 66

### 67 2.2. Study cohort for early stages of CKD

68 Using the Korean NHIS database (NHIS-2019-1-101), subjects who received regular health  
 69 check-up between January 1<sup>st</sup>, 2009 and December 31<sup>st</sup>, 2010 were screened (Figure 1). The inclusion  
 70 criteria were as follows: (1) age 20 to 80 years; (2) without CKD as defined by the estimated  
 71 glomerular filtration rate (eGFR)  $\geq 90$  mL/min/1.73m<sup>2</sup> and negative urine dipstick test at the initial  
 72 health check-up; (3) record of follow-up health check-up at two years  $\pm$  three months from the  
 73 initial health check-up; and (4) fit the CKD diagnostic criteria, as defined by eGFR  $> 60$   
 74 mL/min/1.73m<sup>2</sup>, and a positive urine dipstick test or eGFR between 30 to 59 mL/min/1.73m<sup>2</sup> at the  
 75 follow-up health check-up (index year) [8]. Subjects with missing data on variables included in the  
 76 statistical analysis or already diagnosed as ESRD at index year were excluded.



77  
 78 **Figure 1.** Study design

### 80 2.3. Health-related behaviors

81 Health-related behaviors were assessed based on the self-reported questionnaire included in  
82 the regular health check-up. Sufficient physical activity was defined as (1) 20 minutes or more of  
83 vigorous physical activity, such as running, aerobics, fast bicycling or mountain climbing,  
84 performed at least 3 days a week; or (2) 30 minutes or more of moderate physical activity, such as  
85 fast walking, doubles tennis or bicycling at a regular pace, performed at least 5 days a week; or (3) 4  
86 days of moderate and 1 to 2 days of vigorous physical activity; or (4) 3 days of moderate and 2 days  
87 of vigorous physical activity. A current smoker was defined as having smoked more than 100  
88 cigarettes in a life time and who was currently smoking daily or intermittently. Alcohol  
89 consumption was divided into three levels: heavy drinker, defined as drinking more than 30g  
90 alcohol per day; mild drinker, defined as less than 30g alcohol per day; and nondrinker, defined as  
91 drinking no alcohol at all.

92

### 93 2.4. ESRD and mortality

94 Subjects were followed-up until December 31<sup>st</sup>, 2016 for the outcome event of ESRD or  
95 mortality. ESRD was defined as the relevant International Classification of Diseases, 10th revision,  
96 Clinical Modification (ICD-10-CM) codes (N18-19, Z49, Z94.0, Z99.2) combined with the initiation of  
97 renal replacement therapy (R3280, O7011-O7020 or V001, O7071-O7075 or V003). Death from any  
98 cause was also obtained from the Korean NHIS database.

99

### 100 2.5. Covariate data

101 Demographic data, such as age, sex, area of residence, and income level were collected. Urban  
102 residence was grossly defined as an area with a population of greater than 50,000 according to the  
103 Korean Local Autonomy Act. Subjects in the lowest quantile in national health insurance payment  
104 or recipients of medical aid were grouped into the low income group.

105 Past medical history, such as diabetes mellitus, hypertension, dyslipidemia, and history of  
106 CVD was also gathered. Diabetes mellitus was defined by fasting glucose  $\geq 126$ mg/dL or  
107 ICD-10-CM codes of E11-E14 and at least one claim per year for the prescription of antidiabetic  
108 medication. Hypertension was defined by blood pressure (BP)  $\geq 140/90$  or disease codes of I10-I13,  
109 and I15, and at least one claim per year for the prescription of antihypertensive medication.  
110 Dyslipidemia was defined by total cholesterol  $\geq 240$ mg/dL or a code of E78 and at least one claim  
111 per year for the prescription of lipid lowering medication. History of CVD was determined by  
112 self-report. If subjects answered yes to one of the following two questions, they were considered to  
113 have a history of CVD: (1) Have you been diagnosed or are currently on medication for stroke?; (2)  
114 Have you been diagnosed or are currently on medication for heart disease (myocardial  
115 infarction/angina)?

116 Charlson Comorbidity Index (CCI) was acquired using ICD-10-CM diagnoses of patients [15].  
117 Comorbid conditions were assigned weighted scores based on the relative risk of one year death  
118 from the comorbid condition and summed to yield the CCI score. CCI was categorized into three  
119 groups: 0, 1 and  $\geq 2$ .

120 Blood chemistry test results, such as eGFR (calculated using the Modification of Diet in Renal  
121 Disease (MDRD) equation), fasting plasma glucose level, serum low-density lipoprotein (LDL), and  
122 urine dipstick, body mass index (BMI), and blood pressure, were collected. Fasting glucose, LDL,  
123 BMI, and blood pressure were categorized according to the recommended target values in CKD  
124 patients (Fasting glucose 90-130mg/dL, LDL 70-100mg/dL, BMI 20-25kg/m<sup>2</sup>, BP<130/80mmHg) [8].  
125 Urine dipstick results were categorized as negative, trace, and 1+ or more.

126

127

## 128 2.6. Statistical analysis


129 The baseline characteristics were presented as the mean  $\pm$  standard deviation or as a number  
 130 with percentage. Chi-square test was applied for categorical variables, and Student's *t* test was  
 131 applied for continuous variables to compare the characteristics between the 'Death' and 'No Death'  
 132 groups, as well as between the 'ESRD' and 'No ESRD' groups. Cox proportional hazard regression  
 133 analysis was applied to evaluate the association between health-related behaviors (physical activity,  
 134 smoking, and alcohol) and ESRD and death. The results were adjusted for age, sex, area of  
 135 residence, income, diabetes mellitus, hypertension, dyslipidemia, history of CVD, health-related  
 136 behaviors, categorized CCI, urine dipstick, fasting glucose, LDL, BMI, and BP. Kaplan-Meier curves  
 137 for mortality and ESRD were plotted according to the physical activity, smoking and alcohol. The  
 138 log rank test was performed to analyze the group differences. All statistical analyses were  
 139 performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). A two sided *p* value < 0.05 was  
 140 considered statistically significant.

141

## 142 3. Results

## 143 3.1. Baseline Characteristics

144 A total of 83,470 subjects with early stages of CKD (mean age 48.43 years; mean baseline eGFR  
 145 90.48 mL/min/1.73 m<sup>2</sup>; male 54%) were included in this study (Figure 2). The number of subjects  
 146 who met the target blood pressure of less than 130/80mmHg, fasting glucose of 90 to 130mg/dL,  
 147 LDL of 70 to 100mg/dL, and BMI of 20 to 25 kg/m<sup>2</sup> was 38,825 (46.51%), 46,947 (56.24%), 22,478  
 148 (26.93%), and 43,758 (52.42%) respectively (Table 1).



149

150 **Figure 2.** Patient flow. CKD, Chronic Kidney Disease; ESRD, End Stage Renal Disease.

151

Table 1. Baseline characteristics of study population

N	Death			P Value	ESRD		P Value
	Total	No	Yes		No	Yes	
	83,470	81,664	1,806		83,237	233	
Age, years, mean ± SD	48.43±13.34	48.09±13.16	64.05±12.02	<.001	48.41±13.33	57.24±12.97	<.001
Male, n, (%)	45,108(54.04)	43,835(53.68)	1,273(70.49)	<.001	44,935(53.98)	173(74.25)	<.001
Urban residence, n, (%)	37,732(45.2)	37,064(45.39)	668(36.99)	<.001	37,652(45.23)	80(34.33)	<.001
Low Income, n, (%)	12,956(15.52)	12,562(15.38)	394(21.82)	<.001	12,893(15.49)	63(27.04)	<.001
Diabetes Mellitus, n, (%)	13,047(15.63)	12,383(15.16)	664(36.77)	<.001	12,931(15.54)	116(49.79)	<.001
Hypertension, n, (%)	27,346(32.76)	26,275(32.17)	1,071(59.3)	<.001	27,188(32.66)	158(67.81)	<.001
Dyslipidemia, n, (%)	21,377(25.61)	20,801(25.47)	576(31.89)	<.001	21,275(25.56)	102(43.78)	<.001
History of CVD, n, (%)	1,326(1.59)	1,198(1.47)	128(7.09)	<.001	1,312(1.58)	14(6.01)	<.001
CCI, n, (%)				<.001			<.001
0	42,039(50.36)	41,654(51.01)	385(21.32)		41,994(50.45)	45(19.31)	
1	20,782(24.9)	20,452(25.04)	330(18.27)		20,751(24.93)	31(13.3)	
2 or more	20,649(24.74)	19,558(23.95)	1,091(60.41)		20,492(24.62)	157(67.38)	
Sufficient physical activity, n, (%)	16,854(20.19)	16,550(20.27)	304(16.83)	<.001	16,810(20.2)	44(18.88)	0.619
Smoking, n, (%)				<.001			<.001
No	49,476(59.27)	48,590(59.5)	886(49.06)		49,367(59.31)	109(46.78)	
Ex	13,451(16.11)	13,086(16.02)	365(20.21)		13,405(16.1)	46(19.74)	
Current	20,543(24.61)	19,988(24.48)	555(30.73)		20,465(24.59)	78(33.48)	
Alcohol consumption, n, (%)				<.001			0.007
No	41,602(49.84)	40,533(49.63)	1,069(59.19)		41,466(49.82)	136(58.37)	
Mild	34,622(41.48)	34,102(41.76)	520(28.79)		34,549(41.51)	73(31.33)	
Heavy	7,246(8.68)	7,029(8.61)	217(12.02)		7,222(8.68)	24(10.3)	
eGFR, ml/min/1.73m <sup>2</sup> , n, (%)				<.001			<.001
30-59	16,365(19.61)	15,760(19.3)	605(33.5)		16,269(19.55)	96(41.2)	
60-89	25,042(30)	24,508(30.01)	534(29.57)		24,963(29.99)	79(33.91)	
90-	42,063(50.39)	41,396(50.69)	667(36.93)		42,005(50.46)	58(24.89)	
Urine Dipstick, n, (%)				<.001			<.001
Negative	15,344(18.38)	14,820(18.15)	524(29.01)		15,284(18.36)	60(25.75)	
Trace	39,384(47.18)	38,822(47.54)	562(31.12)		39,341(47.26)	43(18.45)	
1+ or more	28,742(34.43)	28,022(34.31)	720(39.87)		28,612(34.37)	130(55.79)	
Fasting Glucose, n, (%)				<.001			<.001
<90	27,850(33.37)	27,508(33.68)	342(18.94)		27,798(33.4)	52(22.32)	
90-130	46,947(56.24)	45,909(56.22)	1,038(57.48)		46,837(56.27)	110(47.21)	
>130	8,673(10.39)	8,247(10.1)	426(23.59)		8,602(10.33)	71(30.47)	
LDL, mg/dL, n, (%)				<.001			0.059

<70	7,924(9.49)	7,596(9.3)	328(18.16)		7,894(9.48)	30(12.88)	
70-100	22,478(26.93)	21,992(26.93)	486(26.91)		22,407(26.92)	71(30.47)	
>100	53068(63.58)	52076(63.77)	992(54.93)		52,936(63.6)	132(56.65)	
BMI, n, (%)				<.001			0.631
<20	10,247(12.28)	9,960(12.2)	287(15.89)		10,223(12.28)	24(10.3)	
20-25	43,758(52.42)	42,774(52.38)	984(54.49)		43,635(52.42)	123(52.79)	
>25	29,465(35.3)	28,930(35.43)	535(29.62)		27,379(35.3)	86(36.91)	
BP > 130/80mmHg, n, (%)	44,645(53.49)	43,452(53.21)	1,193(66.06)	<.001	44,481(53.44)	164(70.39)	<.001

153 Statistical analysis: chi-square test and Student's *t* test. Abbreviations: SD, standard deviation; CVD,  
 154 cardiovascular disease; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; LDL, low  
 155 density lipoprotein; BMI, body mass index; BP, blood pressure;

### 156 3.2. Health-related behaviors and risk of ESRD and death

#### 157 3.2.1. Physical Activity

158 Approximately 20% of subjects reported to be engaged in sufficient physical activity. There  
 159 was a significantly higher survival rate in the sufficient physical activity group, but no significant  
 160 difference in the ESRD progression rate in the unadjusted Kaplan-Meier analysis (Figure 3a, b). The  
 161 risk of death was significantly decreased in subjects who engaged in sufficient physical activity  
 162 (adjusted Hazard Ratio (HR) 0.73; 95% CI: 0.64-0.83;  $p < 0.001$ ) (Table 2). In addition, a tendency  
 163 towards decreased risk of ESRD was observed, but without statistical significance (adjusted HR  
 164 0.84; 95% CI: 0.60-1.17;  $p = 0.30$ ).

#### 165 3.2.2. Smoking

166 Approximately 25% of the total subjects were current smokers. According to the unadjusted  
 167 Kaplan-Meier analysis, current smokers showed a significantly lower survival rate and higher  
 168 ESRD progression rate (Figure 3c, d). Risk of ESRD and death increased significantly in the current  
 169 smoking group with respective adjusted HR of 1.44 (95% CI: 1.06-1.95;  $p < 0.02$ ), and 1.61 (95% CI:  
 170 1.44-1.80;  $p < 0.001$ ) (Table 2).

#### 171 3.2.3. Alcohol consumption

172 Approximately 50% of total subjects were alcohol drinkers. Alcohol drinkers showed a  
 173 significantly higher survival rate and lower ESRD progression rate in the unadjusted Kaplan-Meier  
 174 analysis (Figure 3e, f). The risk of ESRD and death decreased significantly in the alcohol drinking  
 175 group with adjusted HR of 0.59 (95% CI: 0.44-0.79;  $p < 0.001$ ) and 0.83 (95% CI: 0.74-0.93;  $p < 0.001$ ),  
 176 respectively (Table 2).

177

178

179

180

181

182


183

184  
185**Table 2.** Health-related behaviors and risk of ESRD and death

	N	ESRD	Follow-up duration (person* year)	Crude HR (95%CI)	Adjusted HR (95%CI) <sup>a</sup>	Death	Follow-up duration (person* year)	Crude HR (95%CI)	Adjusted HR (95%CI) <sup>a</sup>
<b>Smoking</b>									
Non, Ex	62,927	155	336,424.23	1(ref.)	1(ref.)	1,251	336,675.06	1(ref.)	1(ref.)
Current	20,543	78	108,623.67	1.41 (1.04,1.90)	1.44 (1.06,1.95)	555	108,733.86	1.7 (1.52,1.90)	1.61 (1.44,1.80)
p-value				0.03	0.02			<.001	<.001
<b>Alcohol</b>									
Non	41,602	136	222,490.34	1(ref.)	1(ref.)	1,069	222,719.88	1(ref.)	1(ref.)
<30g/day or >30g/day	41,868	97	222,557.55	0.60 (0.45,0.80)	0.59 (0.44,0.79)	737	222,689.04	0.87 (0.79,0.97)	0.83 (0.74,0.93)
p-value				<.001	<.001			0.01	<.001
<b>Physical activity</b>									
Insufficient	66,616	189	354,888.68	1(ref.)	1(ref.)	1,502	355,182.57	1(ref.)	1(ref.)
Sufficient	16,854	44	90,159.22	0.79 (0.57,1.1)	0.84 (0.60,1.17)	304	90,226.35	0.69 (0.61,0.78)	0.73 (0.64,0.83)
p-value				0.16	0.30			<.001	<.001

186  
187  
188  
189  
190

<sup>a</sup> Adjusted for age, sex, area of residence, income, diabetes mellitus, hypertension, dyslipidemia, history of CVD, CCI, exercise, smoking, alcohol, urine dipstick, fasting glucose, LDL, BMI, BP  
 Statistical analysis: Cox proportional hazard regression analysis. Abbreviations: ESRD, end stage renal disease; HR, hazard ratio; 95% CI, 95% confidence interval; CVD, cardiovascular disease; CCI, Charlson comorbidity index; LDL, low density lipoprotein; BMI, body mass index; BP, blood pressure;



191 **Figure 3.** Kaplan-Meier curves for end-stage renal disease (ESRD) and mortality according to  
 192 sufficient physical activity (PA) (A, B), smoking (C, D), and alcohol consumption (E, F).

#### 193 4. Discussion

194 Health-related behaviors are associated with disease progression and mortality in CKD  
 195 patients. Subjects who engage in sufficient physical activity had a significantly lower risk of death  
 196 than those with insufficient physical activity. Current smokers had a significantly higher risk of  
 197 ESRD and death than their non-smoking counterparts. Alcohol drinkers had a significantly lower  
 198 risk of ESRD and death than non-drinkers (Table 2).

199 A prospective cohort study, based on the Cardiovascular Health Study, reported that physical  
 200 activity decreased the risk of CKD progression, as defined by a loss of 3.0 ml/min/1.73 m<sup>2</sup> per year  
 201 in GFR [16]. In our study, the risk of CKD progression, as defined by ESRD, was not significantly



202 lower in subjects who engage in sufficient physical activity. This may have been because ESRD as  
203 an endpoint was less sensitive than the decrease in GFR by certain percent or amount. In addition,  
204 the follow-up time of up to 6 years may have been short in detecting the occurrence of ESRD in our  
205 study of subjects with early-stage CKD. A previous study showed that patients had minimal  
206 progression of CKD over a period of 6 years [17].

207 Previous studies reported that physical activity decreased all-cause mortality in the general  
208 population and in ESRD patients on renal replacement therapy [18–20]. Our study reproduced the  
209 results of previous studies in the early-stage CKD population. Although the exact mechanism  
210 remains uncertain, exercise is thought to decrease the risk of death by improving metabolic factors  
211 and decreasing risk of CVD [21]. In addition, physical activity can reduce muscle wasting, which is  
212 a cause of premature death in ESRD patients [22,23]. Despite benefits of physical activity in CKD  
213 patients, only 20% of patients engaged in sufficient physical activity (Table 1). Therefore, more  
214 aggressive life style interventions and systematic efforts are needed in patients in the early-stage  
215 CKD to delay disease progression and possible death.

216 Smoking significantly increased the risk of ESRD and death in early-stage CKD patients. Our  
217 study reproduced the results of previous studies. A recent meta-analysis study showed that current  
218 smokers had an OR of 1.91 (95% CI: 1.39-2.64) for ESRD [6]. Mortality HR for all causes in male and  
219 female current smokers with CKD were 2.26 (95% CI: 1.95-2.63) and 1.78 (95% CI: 1.36-2.32),  
220 respectively [24]. Despite the detrimental effects of smoking on CKD progression and death in CKD  
221 patients, 25% of patients with early-stage CKD were still currently smoking (Table 1). Therefore,  
222 active interventions to quit smoking are also needed to be incorporated in routine health-checkups  
223 with a focus on patients with early-stage CKD.

224 Alcohol consumption was associated with lower risk of ESRD and death in patients with  
225 early-stage CKD. The results of previous studies on the effect of alcohol consumption and risk of  
226 ESRD and death in CKD patients have been mixed. Contrary to our results, a previous  
227 meta-analysis reported a relative risk (RR) of 1.00 (95% CI: 0.55-1.82) for ESRD in CKD patients with  
228 high alcohol consumption [5]. This may have been due to the differences in the method of  
229 comparison of alcohol consumption. Our study compared no alcohol consumption with alcohol  
230 consumption, while the meta-analysis compared alcohol consumption with high alcohol  
231 consumption. A previous study reported a mortality risk for alcohol consumption of more than 2  
232 drinks a week in CKD patients as 0.67 (95% CI: 0.48-0.94) [10]. Alcohol is thought to prevent  
233 hyalinization of renal arterioles, increase high-density lipoprotein (HDL) cholesterol, and reduce  
234 inflammation by controlling the plasma fibrinogen and IL-1 alpha levels [4]. Polyphenol in red wine  
235 has an antioxidant effect. These mechanisms are thought to be involved in the protection of kidney  
236 function with alcohol consumption [4]. However, caution is needed in interpreting these results into  
237 clinical practice, since the optimal alcohol consumption level is not yet clear and may be hard to  
238 control.

239 The strengths of our study are as follows: large sample size of patients in the early stages of  
240 CKD, nationally representative data, and longitudinal follow-up of up to 6 years. Detailed  
241 information from the health-checkup data was used, and possible confounders such as  
242 socioeconomic variables, comorbidities and blood chemistry test results, were included into a  
243 comprehensive analysis.

244 Nonetheless, there are several limitations to consider as well. First, urine dipstick was used in  
245 the definition of CKD instead of proteinuria, which is more sensitive. Second, the data on  
246 health-related behaviors were based on self-report, which may be highly subjective and not very  
247 reliable. Studies have shown that subjects tend to overestimate their physical activity level in  
248 self-reports [25]. However, if physical activity levels were overestimated, it only implies that more  
249 subjects do not engage in sufficient physical activity and that mortality risk can be decreased with  
250 even less physical activity. Similarly subjects tend to underreport alcohol consumption [5]. Since  
251 our study compared the no-alcohol consumption group to the alcohol consumption group, slight  
252 underestimation of alcohol consumption will likely not impact our study results. Third, subjects  
253 who did not receive health check-up were excluded, increasing the risk of selection bias. Fourth, not

254 all possible confounding factors, such as medication or sarcopenia, were considered [26]. Lastly, the  
255 different etiologies of CKD were not taken into consideration.

## 256 5. Conclusions

257 In early CKD patients, sufficient physical activity is associated with decreased risk of mortality.  
258 Smoking is associated with increased risk of ESRD and death. However, only 20% of CKD patients  
259 engaged in sufficient physical activity and 25% of patients continued to smoke. Therefore,  
260 interventions to modify health-related behaviors during the early stages of CKD should be  
261 considered and promoted.

262 **Author Contributions:** Conceptualization, N.J.P., W-S.K. and S.Y.K.; methodology and design, W-S.K, S.Y.K,  
263 K.H., Y.L. and J.J.M.; formal analysis and interpretation, K.H., Y.L., and W-S.K.; writing—original draft  
264 preparation, Y.L.; writing—review and editing, N.J.P., K.H., S.Y.K., J.J.M., Y.L., and W-S.K.; supervision, N.J.P.  
265 and W-S.K. All named authors have read the manuscript, have agreed to the submission, and have participated  
266 in the study to a sufficient extent to be named as authors. All listed authors agreed with the content and  
267 presentation of the paper.

268 **Funding:** This research was supported by the Seoul National University Bundang Hospital Research Fund  
269 (06-2017-257)

270 **Acknowledgments:** This study used the National Health Information Database (NHIS-2019-1-101) made by the  
271 National Health Insurance Service (NHIS).

272 **Conflicts of Interest:** The authors declare no conflict of interest.

## 273 References

- 274 1. Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; Callaghan, A.O.; Lasserson, D.S.; Hobbs, F.D.R. Global  
275 Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *Plosone* **2016**, 1–18.
- 276 2. Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.M.; Yang, C.W.  
277 Chronic kidney disease: Global dimension and perspectives. *Lancet* **2013**, *382*, 260–272.
- 278 3. Nugent, R.A.; Fathima, S.F.; Feigl, A.B.; Chyung, D. The burden of chronic kidney disease on  
279 developing nations: a 21st century challenge in global health. *Nephron. Clin. Pract.* **2011**, *118*, c269-77.
- 280 4. Kanda, E.; Muneyuki, T.; Suwa, K.; Nakajima, K. Alcohol and exercise affect declining kidney function  
281 in healthy males regardless of obesity: A prospective cohort study. *PLoS One* **2015**, *10*, 1–11.
- 282 5. Cheungpasitporn, W.; Thongprayoon, C.; Kittanamongkolchai, W.; Brabec, B.A.; O'corragain, O.A.;  
283 Edmonds, P.J.; Erickson, S.B. High alcohol consumption and the risk of renal damage: A systematic  
284 review and meta-analysis. *Qjm* **2015**, *108*, 539–548.
- 285 6. He, L.; Ma, Z.; Su, X.; Gao, Y.; Xia, J.; Wang, L.; Wang, Y.; Zhong, L. Cigarette smoking and chronic  
286 kidney disease in the general population: a systematic review and meta-analysis of prospective cohort  
287 studies. *Nephrol. Dial. Transplant.* **2017**, *32*, 475–487.
- 288 7. Wakasugi, M.; Kazama, J.J.; Yamamoto, S.; Kawamura, K.; Narita, I. A combination of healthy lifestyle  
289 factors is associated with a decreased incidence of chronic kidney disease: A population-based cohort  
290 study. *Hypertens. Res.* **2013**, *36*, 328–333.
- 291 8. Willis, K.; Cheung, M.; Slifer, S. KDIGO 2012 Clinical Practice Guideline for Evaluation & Management  
292 of CKD. *Kidney Int. Suppl.* **2013**, *3*.
- 293 9. Izumi, A.; Kitamura, M.; Izawa, K.P. Effects of Exercise Training on Delaying Disease Progression in  
294 Patients with Chronic Kidney Disease: a Review of the Literature. *Rev. Recent Clin. Trials* **2016**, *11*,  
295 333–341.

- 296 10. Shlipak, M.G.; Newman, A.; Peterson, D.; Siscovick, D.; Stehman-Breen, C.; Cushman, M.; Psaty, B.;  
297 Bleyer, A.; Fried, L.F.; Manolio, T.A. Cardiovascular Mortality Risk in Chronic Kidney Disease. *Jama*  
298 **2005**, *293*, 1737.
- 299 11. Barcellos, F.C.; Santos, I.S.; Umpierre, D.; Bohlke, M.; Hallal, P.C. Effects of exercise in the whole  
300 spectrum of chronic kidney disease: A systematic review. *Clin. Kidney J.* **2015**, *8*, 753–765.
- 301 12. Shankar, A.; Klein, R.; Klein, B.E.K. The association among smoking, heavy drinking, and chronic  
302 kidney disease. *Am. J. Epidemiol.* **2006**, *164*, 263–271.
- 303 13. Ryoo, J.H.; Choi, J.M.; Oh, C.M.; Kim, M.G. The association between uric acid and chronic kidney  
304 disease in Korean men: A 4-year follow-up study. *J. Korean Med. Sci.* **2013**, *28*, 855–860.
- 305 14. Song, S.O.; Jung, C.H.; Song, Y.D.; Park, C.Y.; Kwon, H.S.; Cha, B.S.; Park, J.Y.; Lee, K.U.; Ko, K.S.; Lee,  
306 B.W. Background and data configuration process of a nationwide population-based study using the  
307 Korean national health insurance system. *Diabetes Metab. J.* **2014**, *38*, 395–403.
- 308 15. Hude Quan, Vijaya Sundararajan, Patricia Halfon, Andrew Fong, Bernard Burnand, Jean-Christophe  
309 Luthi, L. Duncan Saunders, Cynthia A. Beck, Thomas E. Feasby, W.A.G. Coding Algorithms for  
310 Defining Comorbidities in. *Med Care* **2005**, *43*, 1130–1139.
- 311 16. Cassianne Robinson-Cohen, Ronit Katz, Dariush Mozaffarian, Lorien S Dalrymple, Ian de Boer, Mark  
312 Sarnak, Mike Shlipak, David Siscovick, B.K. Physical Activity and Rapid Decline in Kidney Function.  
313 *Arch Intern Med* **2010**, *169*, 2116–2123.
- 314 17. Altemtam, N.; Russell, J.; El Nahas, M. A study of the natural history of diabetic kidney disease (DKD).  
315 *Nephrol. Dial. Transplant* **2012**, *27*, 1847–1854.
- 316 18. Stack, A.G.; Molony, D.A.; Rives, T.; Tyson, J.; Murthy, B.V.R. Association of physical activity with  
317 mortality in the US dialysis population. *Am. J. Kidney Dis.* **2005**, *45*, 690–701.
- 318 19. Wen, C.P.; Wai, J.P.M.; Tsai, M.K.; Yang, Y.C.; Cheng, T.Y.D.; Lee, M.C.; Chan, H.T.; Tsao, C.K.; Tsai,  
319 S.P.; Wu, X. Minimum amount of physical activity for reduced mortality and extended life expectancy:  
320 A prospective cohort study. *Lancet* **2011**, *378*, 1244–1253.
- 321 20. Beddhu, S.; Baird, B.C.; Zitterkoph, J.; Neilson, J.; Greene, T. Physical Activity and Mortality in Chronic  
322 Kidney Disease (NHANES III). *Clin. J. Am. Soc. Nephrol.* **2009**, *4*, 1901–1906.
- 323 21. Stump, C.S. Physical Activity in the Prevention of Chronic Kidney Disease. *Cardiorenal Med.* **2011**, *1*,  
324 164–173.
- 325 22. Stenvinkel, P.; Carrero, J.J.; Von Walden, F.; Ikizler, T.A.; Nader, G.A. Muscle wasting in end-stage renal  
326 disease promulgates premature death: Established, emerging and potential novel treatment strategies.  
327 *Nephrol. Dial. Transplant.* **2016**, *31*, 1070–1077.
- 328 23. Xiaonan H. Wang, Mitch, W.E. Mechanisms of muscle wasting in chronic kidney disease. *Nat Rev*  
329 *Nephrol.* **2014**, *10*, 504–516.
- 330 24. Nakamura, K.; Nakagawa, H.; Murakami, Y.; Kitamura, A.; Kiyama, M.; Sakata, K.; Tsuji, I.; Miura, K.;  
331 Ueshima, H.; Okamura, T. Smoking increases the risk of all-cause and cardiovascular mortality in  
332 patients with chronic kidney disease. *Kidney Int.* **2015**, *88*, 1144–1152.
- 333 25. Lee, P.H.; Macfarlane, D.J.; Lam, T.H.; Stewart, S.M. Validity of the international physical activity  
334 questionnaire short form (IPAQ-SF): A systematic review. *Int. J. Behav. Nutr. Phys. Act.* **2011**, *8*, 115.
- 335 26. Souza, V.A. de; Oliveira, D. de; Mansur, H.N.; Fernandes, N.M. da S.; Bastos, M.G. Sarcopenia in  
336 Chronic Kidney Disease. *J. Bras. Nefrol.* **2015**, *37*.
- 337
- 338